Due to the plethora of new approaches being used in modern drug discovery by the pharmaceutical industry, Current Drug Discovery Technologies has been established to provide comprehensive overviews of all the major modern techniques and technologies used in drug design and discovery. The journal is the forum for publishing original research papers, full-length/mini reviews, drug clinical trial studies and guest edited thematic issues describing novel approaches and cutting edge technologies used in all stages of drug discovery. The journal addresses the multidimensional challenges of drug discovery science including integration issues of the drug discovery process.
Current Drug Discovery Technologies is an essential journal for all scientists and research managers involved in drug discovery who wish to keep abreast of all the modern techniques and technologies used in drug discovery.
Ali H. El-Far*, Babatunji E. Oyinloye, Masood Sepehrimanesh, Mahmoud A. Gab Allah, Ibrahim Abu-Reidah, Hazem M. Shaheen, Iman Razeghian-Jahromi, Abd el-wahab A. Alsenosy, Ahmed E. Noreldin, Soad K. Al Jaouni and Shaker A. Mousa*
Vladimir P. Torchilin (68301 citations) Department of Pharmaceutical Science Center for Pharmaceutical Biotechnology and Nanomedicine Northeastern University Boston, MA 02115 (USA) Biography
Biography of Vladimir P. Torchilin
Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 44,000 citations of his papers with H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.